# A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

> **NCT01712217** · PHASE1,PHASE2 · COMPLETED · sponsor: **Astex Pharmaceuticals, Inc.** · enrollment: 220 (actual)

## Conditions studied

- Non-small Cell Lung Cancer(NSCLC)

## Interventions

- **DRUG:** AT13387
- **DRUG:** Crizotinib

## Key facts

- **NCT ID:** NCT01712217
- **Lead sponsor:** Astex Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2016-12
- **Final completion:** 2017-05-16
- **Target enrollment:** 220 (ACTUAL)
- **Last updated:** 2024-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01712217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01712217, "A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01712217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*